Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
6.86
+0.01 (0.15%)
Aug 15, 2025, 1:43 PM - Market open
Company Description
Exicure, Inc. does not have significant operations.
Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Exicure, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Andy Yoo |
Contact Details
Address: 400 Seaport Court, Suite 102 Redwood City, California 94063 United States | |
| Phone | 847 673 1700 |
| Website | exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M3097 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andy Yoo | Chief Executive Officer, President and Director |
| Seung Ik Baik | Chief Financial Officer, Secretary and Director |
| Joshua Miller | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 8, 2025 | 8-K | Current Report |
| Aug 4, 2025 | 8-K | Current Report |
| Jul 22, 2025 | EFFECT | Notice of Effectiveness |
| Jul 22, 2025 | 424B3 | Prospectus |
| Jul 11, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 27, 2025 | 10-Q | Quarterly Report |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 10, 2025 | 8-K | Current Report |
| May 28, 2025 | 8-K | Current Report |